Uganda Virus Research Institute, Entebbe, Uganda.
Central Public Health Laboratories, Kampala, Uganda.
PLoS One. 2022 May 10;17(5):e0265334. doi: 10.1371/journal.pone.0265334. eCollection 2022.
The objective of this study was to evaluate the performance of seven antigen rapid diagnostic tests (Ag RDTs) in a clinical setting to identify those that could be recommended for use in the diagnosis of SARS-CoV-2 infection in Uganda.
This was a cross-sectional prospective study. Nasopharyngeal swabs were collected consecutively from COVID-19 PCR positive and COVID-19 PCR negative participants at isolation centers and points of entry, and tested with the SARS-CoV-2 Ag RDTs. Test sensitivity and specificity were generated by comparing results against qRT-PCR results (Berlin Protocol) at a cycle threshold (Ct) cut-off of ≤39. Sensitivity was also calculated at Ct cut-offs ≤29 and ≤33.
None of the Ag RDTs had a sensitivity of ≥80% at Ct cut-off values ≤33 and ≤39. Two kits, Panbio™ COVID-19 Ag and VivaDiag™ SARS-CoV-2 Ag had a sensitivity of ≥80% at a Ct cut-off value of ≤29. Four kits: BIOCREDIT COVID -19 Ag, COVID-19 Ag Respi-Strip, MEDsan® SARS-CoV-2 Antigen Rapid Test and Panbio™ COVID-19 Ag Rapid Test had a specificity of ≥97%.
This evaluation identified one Ag RDT, Panbio™ COVID-19 Ag with a performance at high viral load (Ct value ≤29) reaching that recommended by WHO. This kit was recommended for screening of patients with COVID -19-like symptoms presenting at health facilities.
本研究旨在评估七种抗原快速诊断检测(Ag RDT)在临床环境中的性能,以确定哪些检测可推荐用于乌干达 SARS-CoV-2 感染的诊断。
这是一项横断面前瞻性研究。在隔离中心和入境点,连续采集 COVID-19 PCR 阳性和 COVID-19 PCR 阴性参与者的鼻咽拭子,并使用 SARS-CoV-2 Ag RDT 进行检测。通过比较与 qRT-PCR 结果(柏林协议)在循环阈值(Ct)截止值≤39 的结果,生成检测的敏感性和特异性。还在 Ct 截止值≤29 和≤33 计算了敏感性。
在 Ct 截止值≤33 和≤39 时,没有一种 Ag RDT 的敏感性≥80%。两种试剂盒,Panbio™ COVID-19 Ag 和 VivaDiag™ SARS-CoV-2 Ag 在 Ct 截止值≤29 时具有≥80%的敏感性。四种试剂盒:BIOCREDIT COVID-19 Ag、COVID-19 Ag Respi-Strip、MEDsan® SARS-CoV-2 抗原快速检测和 Panbio™ COVID-19 Ag 快速检测的特异性均≥97%。
这项评估确定了一种 Ag RDT,即 Panbio™ COVID-19 Ag,在高病毒载量(Ct 值≤29)时具有符合世卫组织建议的性能。该试剂盒被推荐用于筛查在医疗机构就诊的具有 COVID-19 样症状的患者。